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Background: Osteoarthritis is the most widespread joint-affecting disease. Patients with osteoarthritis experience
pain and impaired mobility resulting in marked reduction of quality of life. A progressive cartilage loss is responsible
of an evolving disease difficult to treat. The characteristic of chronicity determines the need of new active disease
modifying drugs. Aim of the present research is to evaluate the role of low doses of native type II collagen in the
rat model of osteoarthritis induced by sodium monoiodoacetate (MIA).
Methods: 1, 3 and 10 mg kg-1 porcine native type II collagen were daily per os administered for 13 days starting
from the day of MIA intra-articular injection.
Results: On day 14, collagen-treated rats showed a significant prevention of pain threshold alterations induced by
MIA. Evaluation were performed on paws using mechanical noxious (Paw pressure test) or non-noxious (Electronic
Von Frey test) stimuli, and a decrease of articular pain was directly measured on the damaged joint (PAM test). The
efficacy of collagen in reducing pain was as higher as the dose was lowered. Moreover, a reduced postural
unbalance, measured as hind limb weight bearing alterations (Incapacitance test), and a general improvement of
motor activity (Animex test) were observed. Finally, the decrease of plasma and urine levels of CTX-II (Cross Linked
C-Telopeptide of Type II Collagen), a biomarker of cartilage degradation, suggests a collagen-dependent decrease
of structural joint damage.
Conclusions: These results describe the preclinical efficacy of low dosages of native type II collagen as pain reliever
by a mechanism that involves a protective effect on cartilage.
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Osteoarthritis pathophysiology involves the whole joint
in a disease process that includes focal and progressive
loss of hyaline articular cartilage. Concomitant changes
in the bone underneath the cartilage involve formation
of osteophytes and bony sclerosis, as well as alterations
in the synovium and joint capsule [1]. Cartilage loss or
degeneration may be a result of natural aging, obesity,
repeated trauma or hormone disorders. The mechanical
stress on the damaged joint irritates and inflames the
cartilage causing joint pain and swelling [2,3].
An integrative treatment of osteoarthritis, or rheuma-
toid arthritis, must consider a supplementation with col-
lagen since it is the most prevalent component of the* Correspondence: lorenzo.mannelli@unifi.it
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distribution, and reproduction in any mediumsolid phase of articular cartilage [4]. The three major
groups of collagen derivatives clinically used for arthritis
treatment are based on the various degrees of hydrolysis
of collagen: gelatin, collagen hydrolysate and native
undenatured collagen [5]. Analogous working mecha-
nisms has been described for gelatin and collagen hy-
drolysate: after oral administration peptides can be used
as building blocks for the cartilage [6-8]. Moreover, it is
hypothesized that collagen hydrolysate also influences
bone metabolism [9,10] or the vascular system involved
in the atheromatous disease of the subchondral bone
[11,12]. For these purposes collagen hydrolysate is dosed
in grams per day (usually 10 g) [13-15]. On the contrary,
undenatured collagen has been reported as beneficial for
articular pain when per os administered in the order of
milligrams [16,17]. Undenatured collagen was preclini-
cally and clinically studied mainly in rheumatoid arthritised Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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suggests a mechanism called oral tolerance, the usual re-
sponse of the gut-associated lymphoid tissue (GALT) to
harmless gut antigens inducing local and systemic im-
munological tolerance [18-20]. The knowledge about the
relevance of low doses of undenatured collagen in osteo-
arthritis are more limited [21] and the absence of an
immune component in the pathology of osteoarthritis
make difficult to assume the oral tolerance as possible
mechanism of collagen action.
In order to verify the efficacy of low doses of porcine
native type II collagen as pain reliever and cartilage
protector, we determined its pharmacological profile in
a rat unilateral osteoarthritis induced by sodium
monoiodoacetate (MIA).
Methods
Animals
For all the experiments described below, male Sprague-
Dawley rats (Harlan, Varese, Italy) weighing approxi-
mately 200-250 g at the beginning of the experimental
procedure were used. Animals were housed in CeSAL
(Centro Stabulazione Animali da Laboratorio, University
of Florence) and used at least one week after their ar-
rival. Four rats were housed per cage (size 26 × 41 cm);
animals were fed with standard laboratory diet and tap
water ad libitum, and kept at 23 ± 1°C with a 12 h light/
dark cycle, light at 7 a.m. All animal manipulations were
carried out according to the European Community
guidelines for animal care (DL 116/92, application of
the European Communities Council Directive of 24
November 1986 (86/609/EEC). The ethical policy of the
University of Florence complies with the Guide for the
Care and Use of Laboratory Animals of the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996; University of Florence assurance number: A5278-
01). Formal approval to conduct the experiments de-
scribed was obtained from the Animal Subjects Review
Board of the University of Florence. Animals were
anaesthetised before cervical dislocation. All efforts were
made to minimize animal suffering and to reduce the
number of animals used.
Monoiodoacetate-induced osteoarthritis
Unilateral osteoarthritis was also induced by injection of
monoiodoacetate (MIA, Sigma-Aldrich) into the knee
joint according to a described method [22,23]. On day 1,
rats were slightly anesthetized by 2% isoflurane, the left
leg skin was sterilized with 75% ethyl alcohol and the
knee located by palpation; then, a 28-gauge needle was
inserted vertically to penetrate the skin and turned dis-
tally for insertion into the articular cavity until a distinct
loss of resistance was felt. 2 mg MIA in 25 μl saline were
delivered into the left articular cavity. Control ratsreceived 25 μL of saline solution (day 1) in the knee joint.
Behavioral and biochemical measures were performed at
day 14.
Drug treatments
Porcine native type II collagen (Bioiberica, Spain) was
suspended in 1% carboxymethylcellulose sodium salt
(CMC) and administered by the per os (p.o.) route. 1, 3
or 10 mg kg-1 collagen were daily administered starting
from the day 1 immediately after MIA injection to the
13th day. Behavioural and biochemical tests were
performed 24 hours after the end of treatments. Control
rats received p.o. CMC every day. For all tests blind ex-
periments were performed.
Paw Pressure test
The nociceptive threshold in the rat was determined
with an analgesimeter (Ugo Basile, Varese, Italy),
according to the method described by [24]. Briefly, a
constantly increasing pressure was applied to a small
area of the dorsal surface of the paw using a blunt con-
ical probe by a mechanical device. Mechanical pressure
was increased until vocalization or a withdrawal reflex
occurred while rats were lightly restrained. Vocalization
or withdrawal reflex thresholds were expressed in grams.
Rats scoring below 40 g or over 80 g during the test
before drug administration were rejected (25%). For an-
algesia measures, mechanical pressure application was
stopped at 120 g.
Von Frey test
The animals were placed in 20 cm x 20 cm plexiglas
boxes equipped with a metallic meshy floor, 20 cm above
the bench. A habituation of 15 minutes was allowed be-
fore the test. An electronic Von Frey hair unit (Ugo
Basile, Varese, Italy) was used: the withdrawal threshold
was evaluated by applying force ranging from 0 to 50
grams with a 0.2 gram accuracy. Punctuate stimulus was
delivered to the mid-plantar area of each anterior paw
from below the meshy floor through a plastic tip and the
withdrawal threshold was automatically displayed on the
screen. Paw sensitivity threshold was defined as the
minimum pressure required to elicit a robust and imme-
diate withdrawal reflex of the paw. Voluntary move-
ments associated with locomotion were not taken as a
withdrawal response. Stimuli were applied on each an-
terior paw with an interval of 5 seconds. The measure
was repeated 5 times and the final value was obtained by
averaging the 5 measures [25].
PAM test
The Pressure Application Measurement (PAM from Ugo
Basile, Italy) was used to measure mechanical pain
threshold of the knee jont. A force transducer (2 mm
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progressive a quantified force was applied for direct
stimulation of the joint. The rate of application of the
force is decided by the operator. The force (gram-force;
gf ) which elicits the animal response (normally, limb
withdrawal) was recorded. The value considered for each
joint was the mean of 5 consecutive measurements. Data
are expressed as the difference between the force toler-
ated on the knee joint contralateral to the injury and the
force tolerated on the ipsilateral one (Δ Force).Incapacitance test
Weight bearing changes were measured using an
incapacitance apparatus (Linton Instrumentation, UK)
detecting changes in postural equilibrium after a hind
limb injury [26]. Rats were trained to stand on their hind
paws in a box with an inclined plane (65° from horizon-
tal). This box was placed above the incapacitance appar-
atus. This allowed us to independently measure the
weight that the animal applied on each hind limb. The
value considered for each animal was the mean of 5
consecutive measurements. In the absence of hind limb
injury, rats applied an equal weight on both hind
limbs, indicating a postural equilibrium, whereas an
unequal distribution of the weight on hind limbs
indicated a monolateral decreased pain threshold. Data
are expressed as the difference between the weight ap-
plied on the limb contralateral to the injury and the
weight applied on the ipsilateral one (Δ Weight).Spontaneous activity meter (Animex)
Locomotor activity in rats was quantified using an
Animex activity meter Type S (LKB, Farad, Sweden) set
to maximum sensitivity. Every movement of rats, which
were placed on the top of the Animex activity meter,
produced a signal due to variation in inductance and
capacity of the apparatus resonance circuit. Signals were
converted automatically to numbers. On the day of the
experiment the cage, containing three rats, were put on
the measuring platform. Activity counts were made for
5 min.CTX-II and CPII levels
On the day 14 plasma and urine samples were collected
and analyzed to measure the Cross Linked C-Telopeptide
of Type II Collagen (CTX-II) levels. Dosages were
performed using ELISA assay (Antibodies online, Germa-
nia) by specific antibody. The method was in accordance to
the procedure described by [27] for plasma and urine meas-
ure, respectively. Plasmatic levels of CPII, the carboxyl
propeptide of type II procollagen, were also evaluated by
ELISA assay (Ibex, Canada) according to [28,29].Statistic analysis
Results were expressed as means ± S.E.M. and the
analysis of variance was performed by ANOVA. A
Bonferroni’s significant difference procedure was used as
post-hoc comparison. P values of less than 0.05 or 0.01
were considered significant. Data were analyzed using
the “Origin 8.1” software.
Results
The pharmacological activity of low dosages of type II
collagen was evaluated in the rat unilateral osteoarthritis
model induced by MIA. 14 days after intra-articular
MIA injection the mechanical withdrawal threshold to a
noxious stimulus was measured by Paw pressure test
(Figure 1). The weight tolerated on the ipsilateral paw
was significantly reduced (42.2 ± 2.0 g) compared to the
contralateral (77.0 ± 4.1 g). 1 mg kg-1 collagen adminis-
tered daily p.o. for 13 days (starting from the day of
MIA injection) increased the withdrawal threshold of
the ipsilateral paw up to 67.5 ± 3.1 g. The doses of 3 and
10 mg kg-1 were significantly active but progressively less
effective. Figure 2 shows the response to a non-noxious
mechanical stimulus evaluated by the Von Frey test. On
day 14 pain threshold of the ipsilateral paw (MIA + ve-
hicle group) was decreased to 14.1 ± 2.0 g as compared
to the contralateral (31.4 ± 4.2 g). Animals treated with
1 mg kg-1 collagen showed an ipsilateral threshold of
25.3 ± 4.0 g; the groups treated with higher dosage toler-
ated a stimulus of about 21 g. In both Paw pressure and
Von Frey tests the pain sensitivity of the contralateral
paw of MIA + vehicle or MIA + collagen groups was not
different with respect to the control (vehicle + vehicle,
data not shown). Articular pain was evaluated by PAM
test, in Figure 3 the difference (Δ Force) between the
force tolerated directly on the knee joint contralateral to
the injury and the force tolerated on the ipsilateral one
was described. Δ Force in control rats (vehicle + vehicle,
36.1 ± 21.1 gf ) was dramatically increased on the day 14
in MIA + vehicle group (129.5 ± 10.1 gf ). Collagen treat-
ment prevented articular pain in a manner inversely pro-
portional to the dose, reaching 15.8 ± 2.7 gf Δ Force in
animals treated with 1 mg kg-1.
Unilateral pain was also able to induce hind limb
weight bearing alterations (Incapacitance test): the differ-
ence between the weight burdened on the contralateral
and the ipsilateral limb was significantly increased in
MIA + vehicle (54.1 ± 5.3 g) with respect to vehicle + ve-
hicle (4.3 ± 3.5). The protective effect of collagen was
shown in Figure 4. Moreover, the Animex test showed a
collagen-dependent improvement of motor activity in-
creasing the number of movements by about 50%
(Figure 5).
Biochemical analysis of biological fluids performed
14 days after MIA injection, allowed to observe a 4 fold
Figure 1 Pain: noxious stimulus, Paw-pressure test. Monoarthritis was induced by injection of MIA into the knee joint. On day 1, 2 mg MIA in
25 μl saline were delivered in the left (ipsilateral) articular cavity. Paw pressure test was performed on day 14. Collagen was suspended in 1%
CMC and daily administered p.o. starting on the 1th day suddenly after MIA. Control animals were treated with vehicle. Each value represents the
mean of 12 rats performed in 2 different experimental set.*P < 0.01 vs the contralateral paw; §P < 0.05 and ^P < 0.01 vs the MIA + vehicle
treated rats.
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compared to the control group (vehicle + vehicle). The
plasmatic CTX-II increase was reduced by 53% in the
rats treated with 1 mg kg-1 collagen and by 40% in
those treated with the higher doses (Figure 6). The
same parameter was increased by MIA also in
urine (2.6 fold with respect to the control); 3 mg kg-1
collagen induced the higher protective effect (75%Figure 2 Pain: non-noxious stimuli. Von Frey test was used to measure t
injection. 1, 3 or 10 mg kg-1 collagen were p.o. administered every day star
with vehicle. Each value represents the mean of 12 rats performed in 2 diff
< 0.01 vs MIA + vehicle treated rats.inhibition compared to MIA + vehicle; Figure 7). 1, 3
and 10 mg kg-1 collagen daily administered p.o. for
14 days, in the absence of articular damage, did not
alter CTX-II levels in plasma and urine (data not
shown). In Table 1 are shown the plasmatic levels of
the collagen synthesis marker CPII. MIA-induced ar-
ticular damage evoked an increase of CPII that is un-
altered by collagen repeated treatments.he response evoked by a mechanical stimulus 14 days after MIA
ting on the 1th day suddenly after MIA. Control animals were treated
erent experimental set.*P < 0.01 vs contralateral paw; §P < 0.05 and ^P
Figure 3 Articular pain, PAM test. The effect of collagen (daily administered starting on the 1th day) on MIA-induced articular damage was
evaluated on day 14. Data are expressed as the difference between the force tolerated on the knee joint contralateral to the injury and the force
tolerated on the ipsilateral one. Control animals were treated with vehicle. Each value represents the mean of 12 rats performed in 2 different
experimental set. *P < 0.01 compared to vehicle + vehicle rats; §P < 0.05 and ^P < 0.01 compared to MIA + vehicle treated rats.
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Osteoarthritis, also called degenerative joint disease, is a
chronic pathology frequently seen in knee, hip, spine
and hand causing pain, stiffness, decreased range of mo-
tion, and reduced quality of life for million people
throughout the world [5]. It is by far the most wide-
spread joint-affecting disease. According to the World
Health Organization, osteoarthritis is the sixth-leading
cause of disability in the world [30], being comparable to
that of asthma [31,32]. It is estimated that it affects over
12% of the total population in the USA [33], compared
with 0.6% for rheumatoid arthritis [34]. The prevalence
of osteoarthritis increases with age because the condi-
tion is not spontaneously reversible [35]. Almost 9.6% ofFigure 4 Hind limb weight bearing alterations, Incapacitance test. The
induced articular damage was evaluated on day 14. Data are expressed as
to the injury and the weight applied on the ipsilateral one. Control animals
performed in 2 different experimental set. *P < 0.01 vs vehicle + vehicle ratmen and 18.0% of women ages 60 years in the world are
thought to have symptomatic osteoarthritis [36]. Given
the increasing incidence of osteoarthritis with age, the
extended life expectancy observed in the Western world
(for example 20% of the Italian population is age >
65 years; [37]) is expected to result in a progressively
higher number of people affected by this pathology.
The usual management of patients with hip or
knee osteoarthritis requires a combination of non-
pharmacological and pharmacological modalities of
therapy. Pharmacological treatments include acet-
aminophen, cyclooxygenase-2 (COX-2) non-selective
and selective oral non-steroidal anti-inflammatory
drugs (NSAIDs), topical NSAIDs and capsaicin, intra-effect of collagen (daily administered starting on day 1) on MIA-
the difference between the weight applied on the limb contralateral
were treated with vehicle. Each value represents the mean of 12 rats
s; §P < 0.05 and ^P < 0.01 vs MIA + vehicle treated rats.
Figure 5 Motor activity alterations, Animex test. Motor capability was observed by measuring the number of movements in 5 minutes on a
free surface. The test was performed 14 days after MIA injection and effect of daily repeated collagen administration starting from the day 1 was
evaluated. Control animals were treated with vehicle. Each value represents the mean of 12 rats performed in 2 different experimental set.
*P < 0.01 compared to vehicle + vehicle rats; §P < 0.05 and ^P < 0.01 compared to MIA + vehicle treated rats.
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glucosamine and/or chondroitin sulphate for symptom
relief. Glucosamine sulphate, chondroitin sulphate and
diacerein have possible structure-modifying effects
[38]. The characteristic of chronicity determines the
need of new active disease modifying drugs.
In the present research osteoarthritis was mimicked in
rats injecting MIA in the knee joint. The intra-articular in-
jection of MIA induces necrosis of condrocytes with de-
crease of cartilage thickness and osteolysis [23], in the
presence of a relevant component of oxidative stress [39].
Kobayashi et al. [40] showed that MIA is able to disorganize
condrocytes and to promote cartilage erosion. TheseFigure 6 CTX-II, plasma levels. On day 1, 2 mg MIA in 25 μl saline were
1% CMC and p.o. daily administered starting on day 1. Control animals wer
analyzed by ELISA kit. Each value represents the mean of 12 rats performed
vehicle rats; §P < 0.05 and ^P < 0.01 compared to MIA + vehicle treated ratalterations are comparable with joint damages typical of
humans affected by osteoarthritis [22,41,42].
In our experiments behavioral and biochemical fea-
tures were evaluated 14 days after MIA injection, when
pain as well as the degenerative articular process are
overt [42,43]. At this time, CTX-II levels were strongly
increased as measured in urine and plasma. CTX-II is a
C-terminal peptide generated by the concerted action of
matrix metalloproteinase (MMPs) on the fibrillar type II
collagen, and it is considered a biomarker of cartilage
degradation [44,45]. Its level was found to correlate with
cartilage loss in animal models of osteoarthritis [46]. In
agreement, clinical studies showed increased CTX-IIdelivered in the left knee articular cavity. Collagen was suspended in
e treated with vehicle. On day 14 plasma samples were collected and
in 2 different experimental set. *P < 0.01 compared to vehicle +
s.
Figure 7 CTX-II, urine levels. On day 1, 2 mg MIA in 25 μl saline were delivered in the left knee articular cavity. Collagen was suspended in 1%
CMC and p.o. daily administered starting on day 1. Control animals were treated with vehicle. On day 14 urine samples were collected and
analyzed by ELISA kit. Each value represents the mean of 12 rats performed in 2 different experimental set. *P < 0.01 with respect to vehicle +
vehicle rats; §P < 0.05 and ^P < 0.01 compared MIA + vehicle treated rats.
Di Cesare Mannelli et al. BMC Musculoskeletal Disorders 2013, 14:228 Page 7 of 9
http://www.biomedcentral.com/1471-2474/14/228levels in patients with osteoathritis compared with con-
trols [47,48].
Type II collagen is the principal molecular component
of mammalian cartilages [4]: the present work is focused
on the study of this fibrous protein as preventive of
MIA-induced articular damage. Different dosages of na-
tive type II collagen were daily administered per os for
14 days starting from the day of MIA injection. 1-10 mg
dose range was chosen on the bases of the efficacy dem-
onstrated in rheumatoid arthritis models [17]. Lower
doses, in particular 1 mg kg-1, was able to strongly
prevent pain behavior when evaluated both as an
increase on suprathreshold stimulation (hyperalgesia-re-
lated measure) or as pain threshold decrease (allodynia-
related measure). Collagen was able to reduce pain on
the paw ipsilateral to the MIA injection. Since articular
pain and joint tenderness are the most frequent and
disabling symptoms [5] we evaluated also the animal re-
sponses to a direct stimulation of knee joint. The effi-
cacy of collagen on reducing articular pain progressively
increased lowering in the dose. Moreover, collagen-
dependent pain relief allowed also to reduce posturalTable 1 CPII levels
CPII LEVELS (ng mL-1)
MIA
vehicle +
vehicle
vehicle collagen
1 mg kg-1
collagen3
mg kg-1
collagen10
mg kg-1
plasma 232 ± 12 454 ± 31* 500 ± 28 486 ± 23 505 ± 32
2 mg MIA/25 μl were delivered in the left knee articular cavity on day 1
Collagen was p.o. daily administered starting on the same day. On day 14
plasma samples were collected and analyzed by ELISA kit. Each value
represents the mean of 6 rats performed in 2 different experimental set.
*P<0.01 compared to vehicle + vehicle rats.unbalance, a feature of disease progression [26], as mea-
sured by hind limb weight bearing alterations. A general
improvement of motor activity was observed.
The behavioral positive effects of collagen may be related
to a prevention of articular damage since CTX-II levels were
reduced in urine and in plasma of collagen-treated rats. On
the other hand, low dosed collagen did not promote the
synthesis of new collagen given that the plasmatic levels of
CPII, the carboxyl propeptide of type II procollagen [28,29],
was not altered by 14 days of collagen treatment.
The higher efficacy of the lower dose and, in general,
the low dosages administered in the present work do not
justify a mechanism founded on cartilage structure sup-
plementation, as confirmed by the lack of CPII increase.
Moreover, cartilage has limited repair capabilities and
cartilage damage is difficult to heal since chondrocytes
are bound in lacunae and they cannot migrate to dam-
aged areas; hyaline cartilage does not have a blood sup-
ply and the deposition of new matrix is slow [49]. Other
working mechanisms remain to be explored.
In rheumatoid arthritis the induction of oral tolerance
was suggested as mechanism for the beneficial effect on
pain evoked by low doses of native collagen [17,50]. The
relevance of oral tolerance has been described for
pathologies related to immune dysregulations and for
autoimmune diseases [51], indeed a complex immune
mechanism contribute to the pathology of rheumatoid
arthritis [16,52]. The proposed mechanism for collagen-
induced oral tolerance is that dendritic cells in the
GALT take up the collagen and present it to T cells to
generate regulatory T cells. Regulatory T cells control
the immune response inducing several inhibitory cyto-
kines, such as transforming growth factor β and
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kines [17,53].
To the actual knowledge osteoarthritis has not im-
mune characteristic, but shares with rheumatoid arthritis
cartilage degradation and the consequent inflammatory
response. The role of oral tolerance in the management
of osteoarthritis remains to be investigated. However,
future research focused on the pharmacodynamic study
of collagen therapeutic effects could offer new insights
in osteoarthritis pathophysiology.
Conclusions
Low dose collagen decrease pain induced by the
intrarticular injection of MIA, a rat model of articular
damage that mimics osteoarthritis alteration. Treated
animals showed a reduced postural unbalance and a
general improvement of motor activity. The decrease
of CTX-II levels in urine and plasma suggests a pro-
tective effect on cartilage. This evidence highlights the
interest for further investigation about the mechanism
of low dose collagen and its relevance in osteoarthritis
therapy.
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